T6260

AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.

ALOX15-IN-2 is a potent inhibitor of ALOX15 linoleate oxygenase activity, inhibiting the oxidation of linoleic acid (LA) and arachidonic acid (AA), the immediate homologs of ALOX15, with IC50s of 1.55 and 2.79 μM, respectively.

RYL-552S is a drug-resistant strain of Plasmodium falciparum that effectively kills the asexual blood stage of the parasite in vitro.

Anticancer agent 48 (compound 48) is a broad-spectrum anticancer agent with anti-proliferative activity, inhibiting microtubule protein polymerization and demonstrating anti-tumor activity in vivo. It holds potential for studies on solid tumors and haematological tumors.

Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. Anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity, with potential for studies on solid tumours and haematological tumours.

NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.

Flunisolide hemihydrate is a corticosteroid, an orally active Glucocorticoid receptor activator with anti-inflammatory effects. flunisolide hemihydrate induces apoptosis in eosinophils and can be used in asthma or rhinitis, inflammatory diseases. Can be used in studies related to asthma or rhinitis, inflammation.

Compounds 10B and 10C, functioning as cdk4/6 inhibitors, demonstrated low nanomolar activity, optimal antiproliferative effects, excellent metabolic properties, and acceptable pharmacokinetics targeting cdk4/6.

FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).

Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive Rho kinase (ROCK) inhibitor, acting on ROCK I (IC50: 3.7 nM) and ROCK II (IC50: 2.3 nM), and lowers IOP without causing congestion.

MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that targets Akt1 [IC50: 8 nM], Akt2 [IC50: 12 nM], and Akt3 [IC50: 65 nM]. Many breast cancer cell lines, PIK3CA mutants, and PTEN-losing cell lines are sensitive to MK-2206, which exhibits anti-cancer effects.